Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.58
−$0.02 · -0.77%
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Previous close
$2.58
−$0.02 · -0.77%
Regular session · ET · Market data may be delayed.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Day range
Current $2.58
52-week range
Current $2.58
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
56
Mixed
Risk
68
High Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Day range
Current $2.58
52-week range
Current $2.58
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 66.83K USD | 57.77K USD | 34.02K USD |
| Gross profit | — | — | −66.83K USD | −57.77K USD | −34.02K USD |
| Research and development | 5.83M USD | 11.33M USD | 18.38M USD | 16.98M USD | 6.3M USD |
| Selling, general, and administrative | 3.73M USD | 3.41M USD | 7.08M USD | 11.56M USD | 6.04M USD |
| Operating expenses | 9.57M USD | 14.74M USD | 25.46M USD | 28.53M USD | 12.34M USD |
| Interest income | 572K USD | 794K USD | 1.24M USD | 351.62K USD | — |
| Interest expense | — | — | — | 353K USD | 111.08K USD |
| Depreciation and amortization | 70K USD | 53K USD | 67K USD | 57.77K USD | 34.02K USD |
| Operating income | −9.57M USD | −14.74M USD | −25.46M USD | −28.53M USD | −12.38M USD |
| Net income | −9M USD | −13.95M USD | −24.22M USD | −27.65M USD | −12.49M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 26, 2025 | 1:4 | — | — |
Stock split | Mar 17, 2021 | 1:16 | — | — |
Effective Aug 26, 2025
1:4
Effective Mar 17, 2021
1:16
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
